U.S. Stem Cell (USRM)

Executive Summary

U.S. Stem Cell, Inc. is a clinical-stage biotechnology company developing autologous, adipose-derived stem cell and stromal vascular fraction (SVF) therapies for degenerative conditions. Founded in 1999 and based in Sunrise, Florida, the company focuses on harnessing the body's natural healing mechanisms to address unmet medical needs in orthopedics, neurology, and autoimmune disorders. Despite a modest valuation of approximately $64,150 and being privately held with a publicly traded ticker (USRM), the company has not yet achieved FDA approval or commercial sales. Its approach involves extracting a patient's own fat tissue, processing it to isolate stem cells and SVF, and re-administering them to targeted areas. The pipeline remains in early clinical stages, and the company faces significant regulatory and financial hurdles. However, the growing interest in regenerative medicine and the potential for cost-effective, point-of-care therapies could provide opportunities if clinical data proves compelling. U.S. Stem Cell's survival depends on successful trial outcomes, securing funding, and navigating the FDA's evolving framework for cell-based therapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 results for osteoarthritis knee trial35% success
• Q2 2027Strategic partnership or licensing deal for SVF technology20% success
• Q1 2027FDA feedback on pivotal trial design for neurological indication25% success